SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Log In Sign Up Schedule Free 15‑min Call

Top Pharma Companies in India by Market Cap

BSE Sensex 76913.50
582.86 (-0.75%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Anuh Pharma Ltd.	Q V PT	822 Small Cap	81.99 (-0.13%)	19.68	2.42	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Kopran Ltd.	Q V PT	795 Small Cap	164.70 (5.14%)	37.35	1.77	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Sigachi Industries Ltd.	Q V+ PT	767 Small Cap	20.08 (-0.45%)	N/A	1.64	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Fabtech Technologies Ltd.	Q V PT	750 Small Cap	168.70 (-1.11%)	31.27	1.94	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Shree Ganesh Remedies Ltd.	Q V PT	661 Small Cap	514.65 (2.72%)	35.53	4.11	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Nectar Lifesciences Ltd.	Q V+ PT	241 Small Cap	12.40 (-1.43%)	N/A	0.35	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
RPG Life Sciences	2,297.45	13.59%
Syngene Internation.	467.90	8.30%
Guj. Kidney & Super	125.40	5.38%
Kopran	164.70	5.14%
Aarti Pharmalabs	744.25	4.91%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
3B Blackbio Dx	1,206.60	-4.77%
Lincoln Pharma	645.40	-4.19%
Sun Pharma Adv. Res	142.85	-3.71%
Laxmi Denta	199	-3.40%
Guj. Themis Biosyn	363.75	-3.22%

News about Top Pharma Companies in India

28

Apr, 2026

Anuh Pharma informs about press release

Anuh Pharma has informed that the Company has published advertisements in the newspapers Financial Express (English) and Mumbai Lakshdeep (Marathi) editions on Tuesday, 28th April, 2026. This advertisement informs shareholders of Anuh Pharma (‘the Company’) that relate to the initiation of a second phase of 100-day campaign by the Company titled ‘Saksham Niveshak by the Investor Education and Protection Fund Authority (‘IEPFA’), Ministry of Corporate Affairs. Copies of the published advertisements are enclosed herewith. This disclosure is being simultaneously uploaded on the Company’s website: www.anuhpharma.com

The above information is a part of company’s filings submitted to BSE.

28

Apr, 2026

Fabtech Technologies informs about press release

Fabtech Technologies has informed that it enclosed a Press Release on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026. The same is also available on the website of the Company at www.fabtechnologies.com.

The above information is a part of company’s filings submitted to BSE.

18

Apr, 2026

Nectar Lifesciences informs about compliance report

Pursuant to the Regulation 24A of Securities and Exchange of Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and as amended upto date, Nectar Lifesciences has informed that it attached the Annual Secretarial Compliance Report for the year ended on March 31, 2026, duly signed by Company Secretary in practice.

The above information is a part of company’s filings submitted to BSE.

24

Mar, 2026

Kopran informs about closure of trading window

In compliance with the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 as amended and pursuant to the Company’s ‘Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information’, Kopran has informed that the ‘Trading Window’ for dealing in the securities of the Company will remain closed for Directors, Designated Persons and their immediate relatives from April 01, 2026 till forty eight hours after the declaration of Audited Financial Results of the Company for the fourth Quarter and year ended on March 31, 2026. The date of the Board Meeting for inter-alia considering and approving the Audited financial results of the Company for the Fourth Quarter ended and year ended on March 31, 2026 would be intimated in due course.

The above information is a part of company’s filings submitted to BSE.

13

Mar, 2026

Nectar Lifesciences informs about minutes of ordinary and special resolutions

Nectar Lifesciences has informed that the Minutes of the Ordinary and Special Resolutions passed by way of Postal Ballot by the Members of the Company as set out in the Postal Ballot Notice dated January 23, 2026. The Result of the Postal Ballot was declared on March 01, 2026, and communicated to the exchanges vide letter no. NLL/CS/2026- WFH dated March 01, 2026.

The above information is a part of company’s filings submitted to BSE.

07

Mar, 2026

Nectar Lifesciences informs about disclosures

Nectar Lifesciences has informed that this is with reference to letter no. NLL/CS/2024- 414 dated October 07, 2024, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations. Pursuant to captioned regulations, it has enclosed necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure- 1.

The above information is a part of company’s filings submitted to BSE.

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,33,848 Crore
2	Divis Laboratories Ltd.	1,72,697 Crore
3	Torrent Pharmaceuticals Ltd.	1,41,859 Crore
4	Dr. Reddys Laboratories Ltd.	1,10,421 Crore
5	Apollo Hospitals Enterprise Ltd.	1,09,840 Crore
6	Cipla Ltd.	1,05,811 Crore
7	Lupin Ltd.	1,05,320 Crore
8	Max Healthcare Institute Ltd.	96,663 Crore
9	Mankind Pharma Ltd.	92,744 Crore
10	Zydus Lifesciences Ltd.	89,721 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,431	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,192	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,304	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,247	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,099	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,310	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,808	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks